Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation

Current Opinion in Cardiology

Volumn 26, Issue 4, 2011, Pages 294-299

  Stewart, Ralph A H ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

apixaban; atrial fibrillation; dabigatran; idraparinux; rivaroxaban; stroke; ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN ETEXILATE; IDRAPARINUX; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL (TOPIC); DRUG EXCRETION; DRUG HALF LIFE; DYSPEPSIA; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR XA; HEMOSTATICS; HUMANS; STROKE; THROMBIN; WARFARIN;

EID: 79959253430     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283477dbc     Document Type: Review

References (18)

1. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501. (Pubitemid 29482392)
2. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903-1912.
3. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104-123.
4. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-2429.
5. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-934. (Pubitemid 30005032)
6. The Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159:340-347.
7. Olsson SB. Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362:1691-1698. (Pubitemid 37468318)
8. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293:690-698.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
10. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial. Lancet 2008; 371:315-321.
11. Lopes RD, Alexander JH, Al Khatib SM, et al. Apixaban for Reduction in Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159:331-339.
12. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of noninferiority: the ximelagatran experience. J Am Coll Cardiol 2005; 46:1986-1995. (Pubitemid 41713579)
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-1876.
14. Fuster V, Ryden LE, Cannom DS, et al. 2011ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation (Update with Dabigatran). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57:e101-e198.
15. McHaffey K, the AMADEUS study investigators. Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds. http://www.theheart.org 2010. [Accessed 2 April 2011]
16. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-817. Clinical trial demonstrating the oral factor Xa inhibitor apixaban was superior to aspirin for preventing stroke or systemic embolism without increasing the risk of bleeding.
17. Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007; 167:117-124. (Pubitemid 46148058)
18. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975-983. Secondary analysis of RE-LY trial that demonstrated a greater advantage of dabigatran compared with warfarin at sites with poorer INR control.